Edgewise Therapeutics: Raymond James Sees 288% Upside Potential for the Biotech Company!

Edgewise Therapeutics Inc. (EWTX) is a biotech company focused on developing novel therapies for rare neuromuscular diseases. The research and development activities of the company are concentrated on the modulation of muscle proteins to improve muscle function in patients with Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and other conditions. The core of the Edgewise pipeline consists of drug candidates aimed at optimizing muscle contraction and reducing muscle damage. In particular, the main program to mention here is the...